Review: Disruption of the postsynaptic density in Alzheimer's disease and other neurodegenerative dementias

American Journal of Alzheimer's Disease and other Dementias

Volumn 25, Issue 7, 2010, Pages 547-555

  Gong, Yuesong ^a   Lippa, Carol F ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; dementia with Lewy bodies; frontotemporal dementia; postsynaptic density

Indexed keywords

ADAPTOR PROTEIN; AMPA RECEPTOR; APOLIPOPROTEIN E; CHOLINERGIC RECEPTOR; CYTOSKELETON PROTEIN; DOPAMINE RECEPTOR; EPHRIN; EPHRIN RECEPTOR; GLUTAMATE RECEPTOR; INSULIN RECEPTOR; INTEGRIN; LIPOPROTEIN RECEPTOR; METABOTROPIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NERVE CELL ADHESION MOLECULE; SEROTONIN RECEPTOR;

ALZHEIMER DISEASE; DEGENERATIVE DISEASE; DEMENTIA; DENDRITIC SPINE; HUMAN; NERVE CELL PLASTICITY; POSTSYNAPTIC MEMBRANE; PROTEIN AGGREGATION; REVIEW; SYNAPSE;

EID: 77957954675     PISSN: 15333175     EISSN: None     Source Type: Journal    
DOI: 10.1177/1533317510382893     Document Type: Review

References (121)

1. Arvanitakis Z. Update on frontotemporal dementia. Neurologist. 2010 ; 16 (1). 16-22.
2. Ballatore C., Lee VM, Trojanowski JQ Tau mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci. 2007 ; 8 (9). 663-672.
3. Vossel KA, Miller BL New approaches to the treatment of frontotemporal lobar degeneration. Curr Opin Neurol. 2008 ; 21 (6). 708-716.
4. Mandelkow E., von Bergen M., Biernat J., Mandelkow EM Structural principles of tau and the paired helical filaments of Alzheimer's disease. Brain Pathol. 2007 ; 17 (1). 83-90.
5. Terry RD, Masliah E., Salmon DP, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991 ; 30 (4). 572-580. 6. Brun A., Passant U. Frontal lobe degeneration of non-Alzheimer type. Structural characteristics, diagnostic criteria and relation to other frontotemporal dementias. Acta Neurol Scand Suppl. 1996 ; 168: 28-30.
6. Lippa CF, Pulaski-Salo D., Dickson DW, Smith TW Alzheimer's disease, Lewy body disease and aging: a comparative study of the perforant pathway. J Neurol Sci. 1997 ; 147 (2). 161-166.
7. Lipton AM, Cullum CM, Satumtira S., et al. Contribution of asymmetric synapse loss to lateralizing clinical deficits in frontotemporal dementias. Arch Neurol. 2001 ; 58 (8). 1233-1239.
8. Lippa CF Synaptophysin immunoreactivity in Picks disease: comparison with Alzheimer's disease and dementia with Lewy bodies. Am J Alzheimers Dis Other Demen. 2004 ; 19 (6). 341-344.
9. Revuelta GJ, Lippa CF Dementia with Lewy bodies and Parkinson's disease dementia may best be viewed as two distinct entities. Int Psychogeriatr.; 2009 21 (2). 213-216.
10. Gong Y., Lippa CF, Zhu J., Lin Q., Rosso AL Disruption of glutamate receptors at Shank-postsynaptic platform in Alzheimer's disease. Brain Res. 2009 ; 1292: 191-198.
11. Knott GW, Holtmaat A., Wilbrecht L., Welker E., Svoboda K. Spine growth precedes synapse formation in the adult neocortex in vivo. Nat Neurosci. 2006 ; 9 (9). 1117-1124.
12. Harris KM, Stevens JK Dendritic spines of CA 1 pyramidal cells in the rat hippocampus: serial electron microscopy with reference to their biophysical characteristics. J Neurosci. 1989 ; 9 (8). 2982-2997.
13. Wallace W., Bear MF A morphological correlate of synaptic scaling in visual cortex. J Neurosci. 2004 ; 24 (31). 6928-6938.
14. Kim E., Sheng M. PDZ domain proteins of synapses. Nat Rev Neurosci. 2004 ; 5 (10). 771-781.
15. El-Husseini AE, Schnell E., Chetkovich DM, Nicoll RA, Bredt DS PSD-95 involvement in maturation of excitatory synapses. Science. 2000 ; 290 (5495). 1364-1368.
16. Roussignol G., Ango F., Romorini S., et al. Shank expression is sufficient to induce functional dendritic spine synapses in aspiny neurons. J Neurosci. 2005 ; 25 (14). 3560-3570.
17. Gerrow K., Romorini S., Nabi SM, Colicos MA, Sala C., El-Husseini A. A preformed complex of postsynaptic proteins is involved in excitatory synapse development. Neuron. 2006 ; 49 (4). 547-562.
18. Ehlers MD Activity level controls postsynaptic composition and signaling via the ubiquitin-proteasome system. Nat Neurosci. 2003 ; 6 (3). 231-242.
19. Harigaya Y., Shoji M., Shirao T., Hirai S. Disappearance of actin-binding protein, drebrin, from hippocampal synapses in Alzheimer's disease. J Neurosci Res. 1996 ; 43 (1). 87-92.
20. Shim KS, Lubec G. Drebrin, a dendritic spine protein, is manifold decreased in brains of patients with Alzheimer's disease and Down syndrome. Neurosci Lett. 2002 ; 324 (3). 209-212.
21. Hering H., Sheng M. Dendritic spines: structure, dynamics and regulation. Nat Rev Neurosci. 2001 ; 2 (12). 880-888.
22. Yuste R., Bonhoeffer T. Morphological changes in dendritic spines associated with long-term synaptic plasticity. Annu Rev Neurosci. 2001 ; 24: 1071-1089.
23. Carlisle HJ, Kennedy MB Spine architecture and synaptic plasticity. Trends Neurosci. 2005 ; 28 (4). 182-187.
24. Gong Y., Chang L., Viola KL, et al. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci U S A. 2003 ; 100 (18). 10417-10422.
25. Lacor PN, Buniel MC, Chang L., et al. Synaptic targeting by Alzheimer's-related 2-amyloid oligomers. J Neurosci. 2004 ; 24 (45). 10191-10200.
26. Takahashi RH, Almeida CG, Kearney PF, et al. Oligomerization of Alzheimer's beta-amyloid within processes and synapses of cultured neurons and brain. J Neurosci. 2004 ; 24 (14). 3592-3599.
27. Koffie RM, Meyer-Luehmann M., Hashimoto T., et al. Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci U S A. 2009 ; 106 (10). 4012-4007.
28. Boeckers TM The postsynaptic density. Cell Tissue Res. 2006 ; 326 (2). 409-422.
29. Kennedy MB Signal-processing machines at the postsynaptic density. Science. 2000 ; 290 (5492). 750-754.
30. Sheng M. Molecular organization of the postsynaptic specialization. Proc Natl Acad Sci U S A. 2001 ; 98 (13). 7058-7061.
31. Coleman PD, Yao PJ Synaptic slaughter in Alzheimer's disease. Neurobiol Aging. 2003 ; 24 (8). 1023-1027.
32. Shankar GM, Bloodgood BL, Townsend M., Walsh DM, Selkoe DJ, Sabatini BL Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci. 2007 ; 27 (11). 2866-2875.
33. Lesn S., Ali C., Gabriel C., et al. NMDA receptor activation inhibits alpha-secretase and promotes neuronal amyloid-beta production. J Neurosci. 2005 ; 25 (41). 9367-9377.
34. Hoey SE, Williams RJ, Perkinton MS Synaptic NMDA receptor activation stimulates alpha-secretase amyloid precursor protein processing and inhibits amyloid-beta production. J Neurosci. 2009 ; 29 (14). 4442-4460.
35. Gu Z., Liu W., Yan Z. Beta-Amyloid impairs AMPA receptor trafficking and function by reducing Ca2+/calmodulin-dependent protein kinase II synaptic distribution. J Biol Chem. 2009 ; 284 (16). 10639-10649.
36. Armstrong DM, Ikonomovic MD, Sheffield R., Wenthold RJ AMPA-selective glutamate receptor subtype immunoreactivity in the entorhinal cortex of non-demented elderly and patients with Alzheimer's disease. Brain Res. 1994 ; 639 (2). 207-216.
37. Gasparini L., Dityatev A. Beta-amyloid and glutamate receptors. Exp Neurol. 2008 ; 212 (1). 1-4.
38. Procter AW, Qurne M., Francis PT Neurochemical features of frontotemporal dementia. Dement Geriatr Cogn Disord. 1999 ; 10 (suppl 1). 80-84.
39. Mukhin AG, Ivanova SA, Faden AI mGluR modulation of post-traumatic neuronal death: role of NMDA receptors. Neuroreport. 1997 ; 8 (11). 2561-2566.
40. O'Leary DM, Movsesyan V., Vicini S., Faden AI Selective mGluR5 antagonists MPEP and SIB-1893 decrease NMDA or glutamate-mediated neuronal toxicity through actions that reflect NMDA receptor antagonism. Br J Pharmacol. 2000 ; 131 (7). 1429-1437.
41. Allen JW, Eldadah BA, Faden AI Beta-Amyloid-induced apoptosis of cerebellar granule cells and cortical neurons: exacerbation by selective inhibition of group I metabotropic glutamate receptors. Neuropharmacology. 1999 ; 38 (8). 1243-1252.
42. Albasanz JL, Dalf E., Ferrer I., Martán M. Impaired metabotropic glutamate receptor/phospholipase C signaling pathway in the cerebral cortex in Alzheimer's disease and dementia with Lewy bodies correlates with stage of Alzheimer's-disease-related changes. Neurobiol Dis. 2005 ; 20 (3). 685-693.
43. Piggott MA, Owens J., O'Brien J., et al. Muscarinic receptors in basal ganglia in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease. J Chem Neuroanat. 2003 ; 25 (3). 161-173.
44. Jellinger KA Morphological substrates of mental dysfunction in Lewy body disease: an update. J Neural Transm Suppl. 2000 ; 59: 185-212.
45. Levy RB, Aoki C. Alpha7 nicotinic acetylcholine receptors occur at postsynaptic densities of AMPA receptor-positive and -negative excitatory synapses in rat sensory cortex. J Neurosci. 2002 ; 22 (12). 5001-5015.
46. Snyder EM, Nong Y., Almeida CG, et al. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci. 2005 ; 8 (8). 1051-1058.
47. El-Ghundi M., O'Dowd BF, George SR Insights into the role of dopamine receptor systems in learning and memory. Rev Neurosci. 2007 ; 18 (1). 37-66.
48. Liu XY, Chu XP, Mao LM, et al. Modulation of D2R-NR2B interactions in response to cocaine. Neuron. 2006 ; 52 (5). 897-909.
49. Joyce JN, Myers AJ, Gurevich E. Dopamine D2 receptor bands in normal human temporal cortex are absent in Alzheimer's disease. Brain Res. 1998 ; 784 (1-2). 7-17.
50. Kemppainen N., Laine M., Laakso MP, et al. Hippocampal dopamine D2 receptors correlate with memory functions in Alzheimer's disease. Eur J Neurosci. 2003 ; 18 (1). 149-154.
51. Reeves S., Brown R., Howard R., Grasby P. Increased striatal dopamine (D2/D3) receptor availability and delusions in Alzheimer disease. Neurology. 2009 ; 72 (6). 528-534.
52. Piggott MA, Ballard CG, Rowan E., et al. Selective loss of dopamine D2 receptors in temporal cortex in dementia with Lewy bodies, association with cognitive decline. Synapse. 2007 ; 61 (11). 903-911.
53. Hajszan T., MacLusky NJ, Leranth C. Short-term treatment with the antidepressant fluoxetine triggers pyramidal dendritic spine synapse formation in rat hippocampus. Eur J Neurosci. 2005 ; 21 (5). 1299-1303.
54. Jones KA, Srivastava DP, Allen JA, Strachan RT, Roth BL, Penzes P. Rapid modulation of spine morphology by the 5-HT2A serotonin receptor through kalirin-7 signaling. Proc Natl Acad Sci U S A. 2009 ; 106 (46). 19575-19580.
55. Peddie CJ, Davies HA, Colyer FM, Stewart MG, Rodriguez JJ Colocalisation of serotonin2A receptors with the glutamate receptor subunits NR1 and GluR2 in the dentate gyrus: An ultrastructural study of a modulatory role. Exp Neurol. 2008 ; 211 (2). 561-573.
56. Abbas AI, Yadav PN, Yao WD, et al. PSD-95 is essential for hallucinogen and atypical antipsychotic drug actions at serotonin receptors. J Neurosci. 2009 ; 29 (22). 7124-7136.
57. Yuen EY, Jiang Q., Chen P., Feng J., Yan Z. Activation of 5-HT2A/ C receptors counteracts 5-HT1A regulation of n-methyl-D-aspartate receptor channels in pyramidal neurons of prefrontal cortex. J Biol Chem. 2008 ; 283 (25). 17194-17204.
58. Blin J., Baron JC, Dubois B., et al. Loss of brain 5-HT2 receptors in Alzheimer's disease. In vivo assessment with positron emission tomography and [18F]setoperone. Brain. 1993 ; 116 (pt 3). 497-510.
59. Hasselbalch SG, Madsen K., Svarer C., et al. Reduced 5-HT2A receptor binding in patients with mild cognitive impairment. Neurobiol Aging. 2008 ; 29 (12). 1830-1838.
60. Bowen DM, Procter AW, Mann DM, et al. Imbalance of a serotonergic system in frontotemporal dementia: implication for pharmacotherapy. Psychopharmacology (Berl). 2008 ; 196 (4). 603-610.
61. Lai MK, Tsang SW, Alder JT, et al. Loss of serotonin 5-HT2A receptors in the postmortem temporal cortex correlates with rate of cognitive decline in Alzheimer's disease. Psychopharmacology (Berl). 2005 ; 179 (3). 673-677.
62. White MF, Yenush L. The IRS-signaling system: a network of docking proteins that mediate insulin and cytokine action. Curr Top Microbiol Immunol. 1998 ; 228: 179-208.
63. Abbott MA, Wells DG, Fallon JR The insulin receptor tyrosine kinase substrate p58/53 and the insulin receptor are components of CNS synapses. J Neurosci. 1999 ; 19 (17). 7300-7308.
64. De Felice FG, Vieira MN, Bomfim TR, et al. Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc Natl Acad Sci U S A. 2009 ; 106 (6). 1971-1976.
65. Strittmatter WJ, Weisgraber KH, Huang DY, et al. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci U S A. 1993 ; 90 (17). 8098-8102.
66. Coon KD, Myers AJ, Craig DW, et al. A high-density whole-genome association study reveals that apoE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. J Clin Psychiatry. 2007 ; 68 (4). 613-618.
67. Herz J., Chen Y. Reelin, lipoprotein receptors and synaptic plasticity. Nat Rev Neurosci. 2006 ; 7 (11). 850-859.
68. Hoe HS, Harris DC, Rebeck GW Multiple pathways of apolipoprotein E signaling in primary neurons. J Neurochem. 2005 ; 93 (1). 145-155.
69. Hoe HS, Pocivavsek A., Chakraborty G., et al. Apolipoprotein E receptor 2 interactions with the N-methyl-D-aspartate receptor. J Biol Chem. 2006 ; 281 (6). 3425-3431.
70. Gotthardt M., Trommsdorff M., Nevitt MF, et al. Interactions of the low density lipoprotein receptor gene family with cytosolic adaptor and scaffold proteins suggest diverse biological functions in cellular communication and signal transduction. J Biol Chem. 2000 ; 275 (33). 25616-25624.
71. May P., Rohlmann A., Bock HH, et al. Neuronal LRP1 functionally associates with postsynaptic proteins and is required for normal motor function in mice. Mol Cell Biol. 2004 ; 24 (20). 8872-8883.
72. Roberts RC, Xu L., Roche JK, Kirkpatrick B. Ultrastructural localization of reelin in the cortex in post-mortem human brain. J Comp Neurol. 2005 ; 482 (3). 294-308.
73. Botella-Lopez A., Burgaya F., Gaván R., et al. Reelin expression and glycosylation patterns are altered in Alzheimer's disease. Proc Natl Acad Sci U S A. 2006 ; 103 (14). 5573-5578.
74. Knuesel I., Nyffeler M., Mormde C., et al. Age-related accumulation of Reelin in amyloid-like deposits. Neurobiol Aging. 2009 ; 30 (5). 697-716.
75. Hoe HS, Lee KJ, Carney RS, et al. Interaction of reelin with amyloid precursor protein promotes neurite outgrowth. J Neurosci. 2009 ; 29 (23). 7459-7473.
76. Hoe HS, Rebeck GW Functional interactions of APP with the apoE receptor family. J Neurochem. 2008 ; 106 (6). 2263-2271.
77. Wu K., Xu JL, Suen PC, et al. Functional trkB neurotrophin receptors are intrinsic components of the adult brain postsynaptic density. Brain Res Mol Brain Res. 1996 ; 43 (1-2). 286-290.
78. Ji Y., Pang PT, Feng L., Lu B. Cyclic AMP controls BDNFinduced TrkB phosphorylation and dendritic spine formation in mature hippocampal neurons. Nat Neurosci. 2005 ; 8 (2). 164-172.
79. Nagahara AH, Merrill DA, Coppola G., et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease. Nat Med. 2 009; 15 (3). 331-337.
80. Simmons DA, Rex CS, Palmer L., et al. Up-regulating BDNF with an ampakine rescues synaptic plasticity and memory in Huntington's disease knockin mice. Proc Natl Acad Sci U S A. 2009 ; 106 (12). 4906-4911.
81. Gardoni F. MAGUK proteins: new targets for pharmacological intervention in the glutamatergic synapse. Eur J Pharmacol. 2008 ; 585 (1). 147-152.
82. Nyffeler M., Zhang WN, Feldon J., Knuesel I. Differential expression of PSD proteins in age-related spatial learning impairments. Neurobiol Aging. 2007 ; 28 (1). 143-155.
83. Leuba G., Savioz A., Vernay A., et al. Differential changes in synaptic proteins in the Alzheimer frontal cortex with marked increase in PSD-95 postsynaptic protein. J Alzheimers Dis. 2008 ; 15 (1). 139-151.
84. Gylys KH, Fein JA, Yang F., Wiley DJ, Miller CA, Cole GM Synaptic changes in Alzheimer's disease: increased amyloid-beta and gliosis in surviving terminals is accompanied by decreased PSD-95 fluorescence. Am J Pathol. 2004 ; 165 (5). 1809-1817.
85. Christopherson KS, Hillier BJ, Lim WA, Bredt DS PSD-95 assembles a ternary complex with the N-methyl-D-aspartic acid receptor and a bivalent neuronal NO synthase PDZ domain. J Biol Chem. 1999 ; 274 (39). 27467-27473.
86. Lin Y., Jover-Mengual T., Wong J., Bennett MV, Zukin RS PSD-95 and PKC converge in regulating NMDA receptor trafficking and gating. Proc Natl Acad Sci U S A. 2006 ; 103 (52). 19902-19907.
87. Ehrlich I., Klein M., Rumpel S., Malinow R. PSD-95 is required for activity-driven synapse stabilization. Proc Natl Acad Sci U S A. 2007 ; 104 (10). 4176-4181.
88. Baron MK, Boeckers TM, Vaida B., et al. An architectural framework that may lie at the core of the postsynaptic density. Science. 2006 ; 311 (5760). 531-535.
89. Roselli F., Tirard M., Lu J., et al. Soluble beta-amyloid1-40 induces NMDA-dependent degradation of postsynaptic density-95 at glutamatergic synapses. J Neurosci. 2005 ; 25 (48). 11061-11070.
90. Carlisle HJ, Manzerra P., Marcora E., Kennedy MB SynGAP regulates steady-state and activity-dependent phosphorylation of cofilin. J Neurosci. 2008 ; 28 (50). 13673-13683.
91. Ivanov A., Esclapez M., Ferhat L. Role of drebrin A in dendritic spine plasticity and synaptic function: implications in neurological disorders. Commun Integr Biol. 2009 ; 2 (3). 268-270.
92. Hotulainen P., Llano O., Smirnov S., et al. Defining mechanisms of actin polymerization and depolymerization during dendritic spine morphogenesis. J Cell Biol. 2009 ; 185 (2). 323-339.
93. Morishita W., Marie H., Malenka RC Distinct triggering and expression mechanisms underlie LTD of AMPA and NMDA synaptic responses. Nat Neurosci. 2005 ; 8 (8). 1043-1050.
94. Lee-Hoeflich ST, Causing CG, Podkowa M., Zhao X., Wrana JL, Attisano L. Activation of LIMK1 by binding to the BMP receptor, BMPRII, regulates BMP-dependent dendritogenesis. EMBO J. 2004 ; 23 (24). 4792-4801.
95. Davis RC, Maloney MT, Minamide LS, Flynn KC, Stonebraker MA, Bamburg JR Mapping cofilin-actin rods in stressed hippocampal slices and the role of cdc42 in amyloid-beta-induced rods. J Alzheimers Dis. 2009 ; 18 (1). 35-50.
96. Shepherd CE, McCann H., Thiel E., Halliday GM Neurofilamentimmunoreactive neurons in Alzheimer's disease and dementia with Lewy bodies. Neurobiol Dis. 2002 ; 9 (2). 249-257.
97. Hansen LA, Samuel W. Criteria for Alzheimer's disease and the nosology of dementia with Lewy bodies. Neurology. 1997 ; 48 (1). 126-132.
98. Futai K., Kim MJ, Hashikawa T., Scheiffele P., Sheng M., Hayashi Y. Retrograde modulation of presynaptic release probability through signaling mediated by PSD-95-neuroligin. Nat Neurosci. 2007 ; 10 (2). 186-195.
99. Zhong N., Scearce-Levie K., Ramaswamy G., Weisgraber KH Apolipoprotein E4 domain interaction: synaptic and cognitive deficits in mice. Alzheimers Dement. 2008 ; 4 (3). 179-192.
100. Caltagarone J., Jing Z., Bowser R. Focal adhesions regulate Abeta signaling and cell death in Alzheimer's disease. Biochim Biophys Acta. 2007 ; 1772 (4). 438-445.
101. Togashi H., Abe K., Mizoguchi A., Takaoka K., Chisaka O., Takeichi M. Cadherin regulates dendritic spine morphogenesis. Neuron. 2002 ; 35 (1). 77-89.
102. Okabe T., Nakamura T., Nishimura YN, et al. RICS, a novel GTPase-activating protein for Cdc42 and Rac1, is involved in the beta-catenin-N-cadherin and N-methyl-D-aspartate receptor signaling. J Biol Chem. 2003 ; 278 (11). 9920-9927.
103. Fannon AM, Colman DR A model for central synaptic junctional complex formation based on the differential adhesive specificities of the cadherins. Neuron. 1996 ; 17 (3). 423-434.
104. Benson DL, Tanaka H. N-cadherin redistribution during synaptogenesis in hippocampal neurons. J Neurosci. 1998 ; 18 (17). 6892-6904.
105. Silverman JB, Restituito S., Lu W., Lee-Edwards L., Khatri L., Ziff EB Synaptic anchorage of AMPA receptors by cadherins through neural plakophilin-related arm protein AMPA receptor-binding protein complexes. J Neurosci. 2007 ; 27 (32). 8505-8516.
106. Marambaud P., Wen PH, Dutt A., et al. ACBP binding transcriptional repressor produced by the PS1/epsilon-cleavage of N-cadherin is inhibited by PS1 FAD mutations. Cell. 2003 ; 114 (5). 635-645.
107. Uemura K., Kihara T., Kuzuya A., et al. Characterization of sequential N-cadherin cleavage by ADAM10 and PS1. Neurosci Lett. 2006 ; 402 (3). 278-283.
108. Serban G., Kouchi Z., Baki L., et al. Cadherins mediate both the association between PS1 and beta-catenin and the effects of PS1 on beta-catenin stability. J Biol Chem. 2005 ; 280 (43). 36007-36012.
109. Simn AM, de Maturana RL, Ricobaraza A., et al. Early changes in hippocampal eph receptors precede the onset of memory decline in mouse models of Alzheimer's disease. J Alzheimers Dis. 2009 ; 17 (4). 773-786.
110. Shirazi SK, Wood JG The protein tyrosine kinase, fyn, in Alzheimer's disease pathology. Neuroreport. 1993 ; 4 (4). 435-437.
111. Singh TJ, Grundke-Iqbal I., Wu WQ, et al. Protein kinase C and calcium/calmodulin-dependent protein kinase II phosphorylate three-repeat and four-repeat tau isoforms at different rates. Mol Cell Biochem. 1997 ; 168 (1-2). 141-148.
112. Pascale A., Amadio M., Govoni S., Battaini F. The aging brain, a key target for the future: the protein kinase C involvement. Pharmacol Res. 2007 ; 55 (6). 560-569.
113. Ma QL, Yang F., Calon F., et al. p21-activated kinase-aberrant activation and translocation in Alzheimer disease pathogenesis. J Biol Chem. 2008 ; 283 (20). 14132-14143.
114. Salminen A., Suuronen T., Kaarniranta K. ROCK, PAK, and Toll of synapses in Alzheimer's disease. Biochem Biophys Res Commun. 2008 ; 371 (4). 587-590.
115. Wu HY, Hudry E., Hashimoto T., et al. Beta-Amyloid induces the morphological neurodegenerative triad of spine loss, dendritic simplification, and neuritic dystrophies through calcineurin activation. J Neurosci. 2010 ; 30 (7). 2636-2649.
116. Zhao WQ, Santini F., Breese R., et al. Inhibition of calcineurin-mediated endocytosis and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) receptors prevents beta-amyloid oligomer-induced synaptic disruption. J Biol Chem. 2010 ; 285 (10). 7619-7632.
117. Vintm AP, Henriques AG, da Cruz E., Silva OA, da Cruz E., Silva EF PP1 inhibition by Abeta peptide as a potential pathological mechanism in Alzheimer's disease. Neurotoxicol Teratol. 2009 ; 31 (2). 85-88.
118. Wang JZ, Grundke-Iqbal I., Iqbal K. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur J Neurosci. 2007 ; 25 (1). 59-68.
119. Galimberti D., Venturelli E., Gatti A., et al. Association of neuronal nitric oxide synthase C276T polymorphism with Alzheimer's disease. J Neurol. 2005 ; 252 (8). 985-986.
120. Liu F., Shi J., Tanimukai H., et al. Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease. Brain. 2009 ; 132 (pt 7). 1820-1832.
121. Lu KP, Zhou XZ The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signalling and disease. Nat Rev Mol Cell Biol. 2007 ; 8 (11). 904-916.